US 7,320,886 B2 | ||
BGL4 beta-glucosidase and nucleic acids encoding the same | ||
Nigel Dunn-Coleman, Los Gatos, Calif. (US); Frits Goedegebuur, Vlaardingen (Netherlands); Michael Ward, San Francisco, Calif. (US); and Jian Yao, Sunnyvale, Calif. (US) | ||
Assigned to Genecor International, Inc., Palo Alto, Calif. (US) | ||
Filed on Aug. 22, 2005, as Appl. No. 11/208,701. | ||
Application 11/208701 is a division of application No. 10/027000, filed on Dec. 18, 2001, granted, now 7,045,332. | ||
Prior Publication US 2006/0046284 A1, Mar. 02, 2006 | ||
Int. Cl. C12N 9/00 (2006.01); C12N 9/42 (2006.01) |
U.S. Cl. 435—209 [435/4; 435/6; 435/69.1; 435/183; 435/195; 435/200; 435/252.3; 435/320.1; 536/23.2; 536/23.5; 536/23.7] | 1 Claim |
1. A substantially purified BGL4 polypeptide with the biological activity of a β-glucosidase, comprising a sequence selected
from the group consisting of:
(a) an amino acid sequence having at least 95% sequence identity to the amino acid sequence presented in FIG. 2;
(b) the amino acid sequence presented in FIG. 2;
(c) the amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:2;
(d) an amino acid sequence of SEQ ID NO:2;
(e) a substantially purified biologically active fragment of the amino acid sequence of SEQ ID NO:2.
|